Trials / Completed
CompletedNCT06698926
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
A Phase 1 First in Human, Single and Multiple Ascending Dose, Food Effect, and Drug-Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-CLS-616
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-CLS-616 | Oral Tablet |
| DRUG | Placebo | Oral Tablet |
| DRUG | Itraconazole | Oral Capsule |
Timeline
- Start date
- 2024-11-11
- Primary completion
- 2026-01-09
- Completion
- 2026-01-09
- First posted
- 2024-11-21
- Last updated
- 2026-01-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06698926. Inclusion in this directory is not an endorsement.